KRSNAA DIAGNOSTICS LTD Q3 RESULTS
Getting ready to end the 3-year exile: 5 stocks from diagnostics sector with upside potential of up to 53%
There are some businesses, where only a black swan event leads to sharp growth in profit. Otherwise the underlying nature is such that they don't have any sudden spike in their profits. But there is constant growth. The constant growth could be because of many reasons. It may be because of the fact that penetration of that good or service is very low and over a period of time as it improves, both top and bottom line keep moving upward. It could be because of the movement of business from the unorganized sector to the organized sector. Or due the fact that the “need” of that good or service is such that spending on it cannot be postponed. In the case of diagnostic business, it is all the three, or rather four. The fact is that in 2020, a black swan took place which led to the sudden spike in FY 2021 numbers, but then back to normal growth curve. Now for three years, there has been a painful process of partial normalization of valuation and end of price wars. Has the time come for extreme long term investors to bring them back on watchlist ?
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
Apollo Hospitals Q4 Results: Net profit rises 76% YoY to Rs 254 crore
Revenue grew 15% YoY to Rs.4,944 crore in Q4FY24. The earnings before interest, tax, depreciation and ammortisation (EBITDA), EBITDA rose 31% YoY to Rs.640 crore in Q4FY24. The EBITDA margins expanded 161 basis points YoY to 12.95%.
Fortis Healthcare Q4 Results: Net profit jumps 47% YoY to Rs 203 crore
Fortis Healthcare Ltd on Thursday reported a 46.88 per cent increase in consolidated net profit at Rs 203.14 crore in the fourth quarter ended March 2024 on the back of higher revenue from its core business.
Dr Lal PathLabs shares zoom 8% after Q4 results. Should you buy or sell?
Dr Lal PathLabs saw an 8% surge in shares to Rs 2,539.65 on the BSE following a 51% YoY increase in net profit to Rs 86 crore for Q4FY24. Analysts have varying opinions, with Kotak and JM Financial maintaining positive outlooks, while Goldman Sachs remains cautious.
Do Dr Lal Pathlabs' results indicate a turnaround for the sector? 4 stocks from diagnostic space, 3 with upside potential of up to 31%
Some sectors have a company which can be called as the bell weather of that sector and that is why its results of that company probably are indicative of what is happening in the sector. In case of the diagnostic, it is probably the Dr Lals path labs which would fit the criteria, it has national presence, large network, present in both physical and digital segment. So when the quarterly numbers come and they show improvement on many fronts then probably it is time to have a look at them more seriously and see if there is a possible turnaround building in the sector. This became even more important because these stocks had gained extremely high valuation and also popularity in terms of both retail and institutional participation. But then for close to two years, they have been a strong under performer in a strong bull market. Does this result mean that finally in terms of price war for customer acquisition over and now the valuation readjustment will start in the upward direction.
- Go To Page 1
Dr Lal PathLabs Q4 Results: Net profit rises 51% YoY to Rs 86 crore on improved volumes of diagnostic tests
Dr Lal PathLabs on Friday reported a 51% year-on-year (YoY) jump in net profit to Rs 86 crore in the quarter ended March 2024 led by improved volumes of diagnostic tests.
Dr. LalPath Labs Q4 Reslts: Firm posts higher profit on healthy testing demand
Its shares climbed as much as 7.8% after the results before trimming some gains to trade up about 6%. Rival Metropolis Healthcare was up about 2% and Thyrocare Technologies gained about 1%.
Volatility is an integral part of market: 4 midcap stocks from different sectors with potential upside of up to 39%
As the market gets volatile, questions are bound to be raised about whether the mid-cap segment would see a sharp correction or not. Fears about the kind of correction which was seen in March are bound to resurface. More than anything, the best way to navigate such market conditions would be to do two things, first stay with mid-cap stock with some track record in terms of fundamentals and give return to shareholders. Second, once you pick the stock, stay with it long term and dont sell in hurry due to any narrative which some global and domestic development might bring on the table. The reason, volatility is part of any market, but that should not determine your long term investment decisions. ET screener powered by Refinitiv’s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.
Tackling volatility, qualitative & quantitative way: 4 small cap stocks with long term perspective
The way the market slipped on Friday, probably is another reminder that even the best of the bull market corrections are going to come. The problem with the corrective move is that if it sustains for longer, it is the small caps stocks which come under more pressure and shed an inordinate amount of weight. There is a technical reason for this, the liquidity in small caps stocks is lower as compared to large and midcaps. So, whenever there is a selling in this segment, the impact cost is always higher. But the other fact is that if one is able to hold on small at the time when correction is taking place, probability of more than normal return is also higher. But the question is how does one develop the ability to hold onto stocks when the narrative which is being governed by price action becomes so negative. The solution lies in combining a couple of things, which include qualitative and quantitative measure and last but not least ability to ignore noise.
Painful readjustment of valuations over? 4 stocks from diagnostics sector with upside potential of up to 31%
In the last four years, many sectors have made a comeback. However, there are few, who have probably a full life cycle in this short period of time. From all the love on the street which made them touch dizzy heights of valuations. Then a realization that the street is paying too much for them. It is about the diagnostic sector. From being part of a star portfolio manager tops picks, to him admitting that he made a mistake. Diagnostic stocks have seen a cycle. There is another side to the story. Every sector which goes through such cycles in the short term, tends to see a recovery. The only difference is the recovery time, both of the business and getting recognised once again by the street. So, these stocks will make a comeback, whether it happens in one quarter or after years is the question. But one thing is for sure, that if you are a long term investor, don't be in a hurry to get out of the sector.
Process of overvaluations getting readjusted over? 4 stocks from diagnostics sector with upside potential of 18-23%
There are some businesses whose underlying nature is such that they don't have any sudden spike in their profits. However at the same time, there is constant growth. The growth could be because of many reasons, it may be because of the fact that penetration of that good or service is very low and over a period of time as it improves, both top and bottom line keep moving upward. In some cases, it could be because of the movement of business from the unorganized sector to the organized sector. It could also be because of the fact that the need is such that if required spending on it cannot be postponed. In the case of diagnostic business, it is all the three. But there is another side to it, how the street is treating these businesses when it comes to valuations. In case of diagnostics, from dizzy heights of valuation in 2021 to today where it is being seen as a sector where there is nothing worth looking at this point of time due to multiple issues. Yes, there are real issues with the business, but not a bad time to get them on watchlist at least.
Investing in bank, NBFC, automobile, healthcare, FMCG, oil and gas, metal or IT stocks? Know how India Inc performs in Q3
According to data compiled from a Motilal Oswal report, over 33% of the incremental year-on-year growth in Nifty 500 index earnings during the quarter was contributed by Indian Oil, HDFC Bank, Tata Motors, GAIL, and Adani Power. On comparing reported earnings with the expected earnings, most companies in sectors such as energy, construction materials and metals & mining reported earnings higher than Refinitiv estimates. Analysts are bullish on Indian equity markets, citing a stable macro environment with moderated inflation, steady crude prices, easing 10-year G-sec yield and stable currency.
Apollo Hospitals Q3 Results: Net profit rises 60% YoY to Rs 245 crore
Apollo Hospitals on Thursday reported a 60% year-on-year (YoY) jump in net profit to Rs 245 crore in Q3FY24, led by growth across hospital, diagnostics, speciality and pharmacies businesses.
Apollo Hospitals Q3 Results: Cons PAT soars 59% YoY to Rs 245 crore; dividend declared at Rs 6/share
Apollo Hospitals' revenue from operations grew 14% YoY to Rs 4,851 crore, and topped the estimated Rs 4,771 crore. The healthcare services business saw a healthy 13% YoY growth in revenue during the quarter to Rs 2,483 crore, followed by the pharmacy distribution business housed under Apollo Pharmacy, which registered 17% growth in revenue to Rs 2,049 crore.
Fortis Healthcare Q3 Results: Net profit drops 11% YoY to Rs 134 crore
The operating earnings before interest, tax, depreciation and amortisation (EBITDA) rose 6.8% YoY to Rs 284 crore. The EBITDA margins declined 80 basis points to 16.9%.
Q3 results today: Bharti Airtel, Ashok Leyland among 120 companies to announce earnings
Q3 results today: On Saturday, 52 companies including State Bank of India (SBI), Archean Chemical Industries, Affle, Balu Forge, Clean Science and Technology, Gujarat Alkalies & Chemicals and Krishna Institute of Medical Sciences (KIMS).
RBI MPC, Q3 earnings, FII action among 10 factors to drive D-Street action this week
Nifty ended with weekly gains of 2.3% led by IT stocks. PSU Banks outperformed other sectors. Markets will reopen after a holiday week and react to major domestic and global events. RBI will announce monetary policy decisions. US markets closed with strong gains, influencing Indian markets. Several companies will announce Q3FY2024 earnings. Rupee remained flat against the dollar. Corporate actions include ex-dates and record dates for interim dividends. Technical factors and FII/DII action will also impact the market.
Metropolis Healthcare Q3 Results: Net profit drops 25% to Rs 27 crore
"The performance in Q3 was marginally impacted on account of heavy rainfall and floods in Chennai and adjacent areas in December 2023, leading to loss of revenues for approx. 7-8 days from Chennai region, which is one of the focus cities for Metropolis," Ameera Shah, promoter and managing director of Metropolis Healthcare said.
Dr. Lal PathLabs Q3 Results: Firm posts 54% jump in profit on flu, COVID tests
The October-December quarter encompasses the tail end of the monsoon as well as winter, which brings with them ailments such as influenza and stomach flu.
Tata Tech Q3 results today: What will be the key watch outs for Dalal Street?
Tata Technologies Ltd is set to release its earnings for the December quarter today, marking its first earnings release since listing last month. The company reported strong earnings for the six months ended September, with consolidated revenue growing 34% YoY to Rs 2,527 crore and net profit growing 36% YoY to Rs 352 crore.
Price wars are still on but... 4 stocks from diagnostics sector have upside potential of up to 26%
In the last five years, the diagnostic segment of the healthcare sector has seen many ups and downs. During Covid, diagnostic players were overloaded with work and then came the price wars which some new tech companies brought on the table. The price war was essentially started to grab both, market and mind share. While the price war is still on in some segments, there is a possibility that its intensity may come down. The reason, new companies have burnt enough cash and large physical-only players have also made some inroads into digital channels for customer acquisition and also part delivery of the service. Will this bring back focus of the street?
187 companies to release Q2 results on Friday. What to expect from IndiGo, Titan and Zomato
Despite a lower passenger load factor, IndiGo managed to maintain its market share in the quarter. PLF for IndiGo remained muted for the second consecutive month at 83.6%. But IndiGo being able to maintain domestic market share despite lower PLFs indicates better aircraft/pilot availability with it versus other airlines, brokerage ICICI Securities said.
Fortis Healthcare Q1 Results: PAT falls 9% YoY to Rs 122.5 cr
The company, which posted a consolidated profit after tax of Rs 134.3 crore in the first quarter of the last fiscal, said its diagnostics business has been renamed as Agilus Diagnostics Ltd, and the boards of the two firms have granted approval for the latter to initiate an initial public offer (IPO) process
For risk takers: 5 smallcap stocks that have beaten volatile markets can rise up to 58%
As Nifty comes closer to form a new high, more small cap stocks are joining the party. Right from a logistic company of a large industrial house to a diagnostic major to quick service restaurant players are coming on the list. ET screener powered by Refinitiv’s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.
For risk takers: 5 smallcap stocks that have beaten volatile markets can rise up to 52%
As Nifty comes closer to form a new high, more small cap stocks are joining the party. Right from a power and a diagnostic major to an engineering company are coming on the list. ET screener powered by Refinitiv’s Stock Report Plus applies different algorithms & filters to all BSE and NSE stocks, and lists stocks which fulfill the various criteria as specified into the algorithms & filters to find those which might help navigate the stock market.
Dr. Lal PathLabs Q4 Results: Co reports sixth consecutive fall in net profit at Rs 567 million
The medical diagnostics firm, India's largest by revenue, posted a consolidated net profit of 567 million rupees ($6.93 million) in the three months to March 31, down from 613 million rupees a year earlier.
Smallcaps that managed to keep their head above water. 4 stocks with “Strong Buy” & “Buy” reco that can rally up to 59%
These small cap companies have shown positive returns in the last one month at a time when markets have been overwhelmed by news and other developments. ET screener powered by Refinitiv’s Stock Report Plus lists down stocks with high upside potential over the next 12 months, having an average recommendation of “buy” or "strong buy".
Still negatively biased in market; have 6 picks in defence, cap goods & infra: Nischal Maheshwari
“Over ownership and under ownership has played a big role there and if one looks at it, the maximum amount of selling has come from the FIIs during this year. They were large owners of banks and have been continuously selling and that prompted even the domestics to sell off and as the outlook became more murky for the current year, people started trying to identify areas where they could hide and hide comfortably and IT was the best spot to be. ”
Load More
